dr. (Lucas) L.M.A. Goossens

All publications (34)

• Article (33)

  • H. van Eeren, L.M.A. Goossens, R. Scholte, J.J. van Busschbach & R.E.A. van der Rijken (2018). Multisystemic Therapy and Functional Family Therapy Compared on their Effectiveness Using the Propensity Score Method. Journal of Abnormal Child Psychology, 46 (5), 1037-1050. doi: 10.1007/s10802-017-0392-4
  • S.A. Huygens, L.M.A. Goossens, J.A. van Erkelens, J.J.M. Takkenberg & M. Rutten-van Molken (2018). How much does a heart valve implantation cost and what are the health care costs afterwards? Open Heart, 5 (1):UNSP e000672. doi: 10.1136/openhrt-2017-000672
  • J. Hermans, M. Reijman, L.M.A. Goossens, H. Verburg, S.M.A. Bierma-Zeinstra & M.A. Koopmanschap (2018). Cost-Utility Analysis of High Molecular Weight Hyaluronic Acid for Knee Osteoarthritis in Everyday Clinical Care in Patients at a Working Age: An Economic Evaluation of a Randomized Clinical Trial. Arthritis Care & Research, 70 (1), 89-97. doi: 10.1002/acr.23242
  • J. Hermans, M. Reijman, L.M.A. Goossens, H. Verburg, S.M.A. Bierma-Zeinstra & M.A. Koopmanschap (2017). A cost utility analysis of high molecular weight hyaluronic acid for knee osteoarthritis in everyday clinical care. Arthritis Care & Research. doi: 10.1002/acr.23242
  • L.M.A. Goossens, M.P.M.H. van Molken, M.R.S. Boland, B. Donkers, M.F. Jonker, A.H.M. Slok, Ph.L. Salome, C.P. van Schayck, J.C.C.M. in 't Veen & E.A. Stolk (2017). ABC Index: quantifying experienced burden of COPD in a discrete choice experiment and predicting costs. BMJ Open, 7 (12). doi: 10.1136/bmjopen-2017-017831.
  • S. van der Schans, L.M.A. Goossens, M.R.S. Boland, J.W. Kocks, M.J. Postma, J.F. van Boven & M.P.M.H. Rutten - van Molken (2017). Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. Pharmacoeconomics (Print), 35, 43-63. doi: 10.1007/s40273-016-0448-2
  • A.H.M. Slok, D. Kotz, G. van Breukelen, N. Chavannes, M.P.M.H. Rutten - van Molken, H.A.M. Kerstjens, T. van der Molen, G.M. Asijee, P.N.R. Dekhuijzen, S. Holverda, P.L. Salome, L.M.A. Goossens, M. Twellaar, J. van Veen & O. van Schayck (2017). Assessment of Burden of COPD tool: evidence not perception. European Respiratory Journal, 50 (1):1700756. doi: 10.1183/13993003.00756-2017
  • M.R.S. Boland, J.F. van Boven, A.L. Kruis, N. Chavannes, T. Van der Molen, L.M.A. Goossens & M.P.M.H. Rutten - van Molken (2016). Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. Respiratory Medicine, 110, 34-45. doi: 10.1016/j.rmed.2015.11.008
  • L.M.A. Goossens, J. Overbeek, M. Driessen & M.P.M.H. Rutten - van Molken (2016). Effect van therapietrouw op exacerbaties is moeilijk te schatten met beschikbare real life data voor astma en COPD. Pharmaceutisch Weekblad, 1, a1632.
  • C.P. van Schayck, A.H.M. Slok, D. Kotz, G. van Breukelen, N. Chavannes, M.P.M.H. Rutten - van Molken, H.A.M. Kerstjens, T. Van der Molen, G.M. Asijee, P.N.R. Dekhuijzen, S. Holverda, Ph.L. Salome, L.M.A. Goossens, M. Twellaar & J.C.C.M. in 't Veen (2016). Effectiviteit van de 'Ziektelastmeter COPD'. Nederlands Tijdschrift voor Geneeskunde, 160 (47), 16-21.
  • S.S. Tan, CH Teirlinck, J. Dekker, L.M.A. Goossens, A.M. Bohnen, J.A.N. Verhaar, P.P. van Es, B.W. Koes, S. Bierma-Zeinstra, P.A.J. Luijsterburg & M.A. Koopmanschap (2016). Cost-utility of exercise therapy in patients with hip osteoarthritis in primary care. Osteoarthritis and Cartilage, 24 (4), 581-588. doi: 10.1016/j.joca.2015.11.010
  • E.C. Vasbinder, L.M.A. Goossens, M.P.M.H. van Molken, B.C.M. de Winter, L. van Dijk, A.G. Vulto, E.I.M. Blankman, N. Dahhan, M.T.M. Veenstra-van Schie, F.G.A. Versteegh, B.H.M. Wolf, H.M. Janssens & P.M.L.A. van den Bemt (2016). e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial75. European Respiratory Journal, 48 (3), 758-767. doi: 10.1183/13993003.01698-2015
  • A.H.M. Slok, D. Kotz, G. van Breukelen, N. Chavannes, M.P.M.H. Rutten - van Molken, H.A.M. Kerstjens, T. van der Molen, G.M. Asijee, P.N.R. Dekhuijzen, S. Holverda, P.L. Salome, L.M.A. Goossens, M. Twellaar, J.C.C.M. in 't Veen & O. van Schayck (2016). Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care. BMJ Open, 6 (7):e011519. doi: 10.1136/bmjopen-2016-011519
  • C. Selya-Hammer, N.G.R. Guix, M. Baldwin, A. Ternouth, M. Miravitlles, M.P.M.H. Rutten - van Molken, L.M.A. Goossens, N.C. Buyukkaramikli & V. Acciai (2016). Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic Advances in Respiratory Disease, 10 (5), 391-401. doi: 10.1177/1753465816657272
  • L.M.A. Goossens, W.K. Redekop & C.W.M. van Gils (2015). Noncollapsibility and Censoring: What's the Bias in Estimating Effects on Survival? Epidemiology, 26 (1), e1-e2. doi: 10.1097/EDE.0000000000000197
  • M.R.S. Boland, J.F. van Boven, J.W. Kocks, T. Van der Molen, L.M.A. Goossens, N. Chavannes & M.P.M.H. Rutten - van Molken (2015). Mapping the clinical chronic obstructive pulmonary disease questionnaire onto generic preference-based EQ-5D values. Value in Health, 18 (2), 299-307. doi: 10.1016/j.jval.2014.11.006
  • P. Vemer, L.M.A. Goossens & M.P.M.H. Rutten - van Molken (2014). Not Simply More of the Same: Distinguishing between Patient Heterogeneity and Parameter Uncertainty. Medical Decision Making, 34 (8), 1048-1058. doi: 10.1177/0272989X14550499
  • L.M.A. Goossens, C.M.A. Utens, F.W. Smeenk, B. Donkers, C.P. van Schayck & M.P.M.H. Rutten - van Molken (2014). Should I stay or should I go home? A latent class analysis of a discrete choice experiment on hospital-at-home. Value in Health, 17 (5), 588-596. doi: 10.1016/j.jval.2014.05.004
  • L.M.A. Goossens, I. Leimer, N. Metzdorf, K. Becker & M.P.M.H. Rutten - van Molken (2014). Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Public Health, 14, 163. doi: 10.1186/1471-2466-14-163
  • C.M.A. Utens, L.M.A. Goossens, C.P. van Schayck, M.P.M.H. Rutten - van Molken, F.W. Smeenk, M. van Vliet, W. Seezink & D.R. DeMunck (2014). Informal caregiver strain, preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: results of a randomised controlled trial. International Journal of Nursing Studies, 51 (8), 1093-1102. doi: 10.1016/j.ijnurstu.2014.01.002
  • L.M.A. Goossens, C.M.A. Utens, F.W.J.M. Smeenk, O.C.P. van Schayk, M. van Vliet, W. van Litsenburg, M.W. Braken & M.P.M.H. Rutten - van Molken (2013). Cost-Effectiveness of Early Assisted Discharge for COPD Exacerbationsin The Netherlands. Value in Health, 16 (4), 517-528. doi: 10.1016/j.jval.2013.01.010
  • C.M.A. Utens, L.M.A. Goossens, O.C.P. van Schayk, M.P.M.H. Rutten - van Molken, M.W. Braken, L.M.G.A. van Eijsden & F.W.J.M. Smeenk (2013). Evaluation of health care providers' role transition and satisfaction in hospital-at-home for chronic obstructive pulmonary disease exacerbations: a survey study. Bmc Health Services Research, 13, 1-26. doi: 10.1186/1472-6963-13-363
  • C.M.A. Utens, L.M.A. Goossens, O.C.P. van Schayk, M.P.M.H. Rutten - van Molken, W. van Litsenburg, A. Janssen, A. van der Pouw & F.W.J.M. Smeenk (2013). Patient preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: Results of a randomised controlled trial. International Journal of Nursing Studies, 50 (11), 1537-1549. doi: 10.1016/j.ijnurstu.2013.03.006
  • M.P.M.H. Rutten - van Molken & L.M.A. Goossens (2012). Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. Pharmacoeconomics (Print), 30 (4), 271-302. doi: 10.2165/11589270-000000000-00000
  • C.M.A. Utens, L.M.A. Goossens, F.W.J.M. Smeenk, M.P.M.H. Rutten - van Molken, M. van Vliet, M.W. Braken, L.M.G.A. van Eijsden & C.P. van Schayck (2012). Early assisted discharge with generic community nursing for chronic obstructive pulmonary disease exacerbations:results of a randomised controlled trial. BMJ Open, 2, 1-8. doi: 10.1136/bmjopen-2012-001684
  • L.M.A. Goossens, M.C. Nivens, P. Sachs, B. Monz & M.P.M.H. Rutten - van Molken (2011). Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respiratory Medicine, 105 (1195-1202), 1195-1202. doi: 10.1016/j.rmed.2011.02.018
  • L.M.A. Goossens, C.L. Baker, B. Monz, K.H. Zou & M.P.M.H. Rutten - van Molken (2011). Adjusting for COPD severity in database research: developing and validating an algorithm. International Journal of COPD, 2011 (6), 669-678. doi: 10.2147/COPD.S26214
  • C.M.A. Utens, L.M.A. Goossens, F.W.J.M. Smeenk, C.P. van Schayck, W. van Litsenburg, A. Janssen, M. van Vliet, W. Seezink, D.R.A.J. Demunck, B. van de Pas, P.J. de Bruijn, A. van der Pouw, J.M.A.M. Retera, P. de Laat-Bierings, L. van Eijsden, M. Braken, R. Eijsermans & M.P.M.H. Rutten - van Molken (2010). Effectiveness and cost-effectiveness of early assisted discharge for Chronic Obstructive Pumonary Disease exacerbations: the design of a randomised controlled trial. BMC Public Health, 10 (618), 1-12. doi: 10.1186/1471-2458-10-618
  • L. Hakkaart-van Roijen, S.S. Tan, L.M.A. Goossens, S.J. Schawo, W.B.F. Brouwer, M.P.M.H. Rutten - van Molken & F.F.H. Rutten (2010). Doelmatigheid in praktijkrichtlijnen voor medicijnen: resultaten van een 'quick scan'. TSG, 4 (88), 175-181.
  • L.M.A. Goossens, R.A. Riemersma, D.S. Postma, T. van der Molen & M.P.M.H. Rutten - van Molken (2009). An Economic Evaluation of Budesonide/Formoterol for Maintenance and Retriever Treatment in Asthma in General Practice. Advances in Therapy, 26 (9), 872-885. doi: 10.1007/s12325-009-0063-0
  • L.M.A. Goossens, B. Standaert, N.G. Hartwig, A.M. Hovels & M.J. Al (2009). Conclusions on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Vaccine, 27, 2531-2532. doi: 10.1016/j.vaccine.2009.02.036
  • L.M.A. Goossens, B. Standaert, N.G. Hartwig, A.M. Hovels & M.J. Al (2008). The cost-utility of rotavirus vaccination with Rotarix TM (RIX4414) in the Netherlands. Vaccine, 26, 1118-1127. doi: 10.1016/j.vaccine.2007.11.070
  • L.M.A. Goossens, P.D. Knoester & M.P. Rutten-van Mölken (2008). Avastin (bevacizumab), Macugen (pegaptanib) en Lucentis (ranibizumab): vergelijking van medicatiekosten. Pharmaceutisch Weekblad, 2 (4), 75-79.

• Doctoral thesis (1)

  • L.M.A. Goossens (2013, januari 18). Underestimated uncertainties: hospital-at-home for COPD exacerbations and methodological issues in the economic evaluation of healthcare. EUR (215 pag.) (Rotterdam) Prom./coprom.: prof.dr. M.P.M.H. Rutten - van Molken, C.P. van Schayck & dr. W.K. Redekop.

Ancillary activities (1)

Present position